Regeneron drugs said that Monday will purchase a 236 million genetic test company that has been purchased by $ 256 million, and has promised the ethical use of customer DNA data.
Through the agreement, Regenerón says, directing his skills in the discovery of Genomics has aimed at 23 million customers by integrating more than 23 million DNA profiles, Direct Saliva tests for COSS-Consume.
However, the transaction has focused on data privacy issues, especially about 23arm’s latest challenges.
The genomics company was a trailblarter during the DNA tests, with his test kits and damage to weak damage in 2023 to explain the genetic data of millions of customers. The company has collected 15 million genetic customer data with DNA testing kits online and has given salt samples.
Hack and the following bankruptcy archive has studied legislators and have been able to sell customer genetic data to unscrupulous buyers.
Regeneron said that 23arm’s privacy policy and complies with applicable laws in terms of use of customer data.
The drug also committed to working with a independent supervisor of the court, which will assess the implications of consumer privacy and expected to deliver the report to the judge until June 10.
The Court must be taken into account the acceptance of the transaction on June 17.
Genomics investments have a “good strategic sense” for regeneron, but can last a decade to see a return, Bernstain William Pickerling said.
“Seeing regeneron tracking record, we believe that 23ardMe customers are in good hands from a privacy point of view,” the selector has been added.
As part of the agreement, Regeneron will acquire all 23rd units, except TeleHealth Service LemonAid, which aims to plan the wind companies in the genetic test.
After the transaction, it is expected to complete in the third quarter, 23Andm will work as a fully owned unit in Regenero.
2025-05-19 12:38:00
